SCHEMBL6844284

SCHEMBL6844284

CC(C)c1ccc(S(=O)(=O)Nc2ccc3c(ccn3-c3cccnc3)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD1 O95696 5/20 0.53
BRPF1 P55201 5/20 0.53
TRIM24 O15164 1/20 0.53
POLB P06746 1/20 0.51
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
ADRB3 P13945 2/20 0.46
BRPF3 Q9ULD4 3/20 0.46
BRD4 O60885 2/20 0.46
BRD9 Q9H8M2 2/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PKM P14618 1/20 0.43
HTR6 P50406 2/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
PGR P06401 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840912 0.89 POLB (0.54) BRD1BRPF1POLBBRPF3BRD4
SCHEMBL6844273 0.87 BRD4 (0.57) BRD1BRPF1TRIM24POLBBRPF3
SCHEMBL6656125 0.86 MEN1 (0.57) BRD1BRPF1BRPF3BRD4BRD9
SCHEMBL6847813 0.86 KEAP1 (0.60) BRD1BRPF1TRIM24BRPF3BRD4
SCHEMBL6846145 0.86 ALDH1A1 (0.60) BRD1BRPF1POLBBRPF3BRD4
SCHEMBL6845454 0.84 KMT2A (0.51) BRD1BRPF1POLBBRPF3BRD4
SCHEMBL6659457 0.84 KMT2A (0.48) BRD1BRPF1POLBBRPF3BRD4
SCHEMBL6658847 0.84 BRPF1 (0.60) BRD1BRPF1BRPF3BRD4BRD9
SCHEMBL6844486 0.82 KMT2A (0.47) BRD1BRPF1ADRB2ADRB1ADRB3
SCHEMBL6845979 0.81 BRPF1 (0.53) BRD1BRPF1POLBBRPF3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 BRD1 1341/4885BRPF1 2930/4885TRIM24 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.